Head and neck cancer
LQM Chow - New England Journal of Medicine, 2020 - Mass Medical Soc
Head and Neck Cancer Most head and neck cancers (73% in the United States) are now
related to human papillomavirus infection rather than tobacco and alcohol. Primary cancers …
related to human papillomavirus infection rather than tobacco and alcohol. Primary cancers …
[HTML][HTML] Oncologic photodynamic therapy: basic principles, current clinical status and future directions
D Van Straten, V Mashayekhi, HS De Bruijn, S Oliveira… - Cancers, 2017 - mdpi.com
Photodynamic therapy (PDT) is a clinically approved cancer therapy, based on a
photochemical reaction between a light activatable molecule or photosensitizer, light, and …
photochemical reaction between a light activatable molecule or photosensitizer, light, and …
Graph deep learning for the characterization of tumour microenvironments from spatial protein profiles in tissue specimens
Multiplexed immunofluorescence imaging allows the multidimensional molecular profiling of
cellular environments at subcellular resolution. However, identifying and characterizing …
cellular environments at subcellular resolution. However, identifying and characterizing …
Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial
PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of …
RI Haddad, K Harrington, M Tahara… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE CheckMate 651 (ClinicalTrials. gov identifier: NCT02741570) evaluated first-line
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …
[HTML][HTML] Immune landscape of viral-and carcinogen-driven head and neck cancer
Head and neck squamous cell carcinoma (HNSCC) arises through exposure to
environmental carcinogens or malignant transformation by human papillomavirus (HPV) …
environmental carcinogens or malignant transformation by human papillomavirus (HPV) …
[HTML][HTML] Single-cell transcriptome profiling of the stepwise progression of head and neck cancer
JH Choi, BS Lee, JY Jang, YS Lee, HJ Kim… - Nature …, 2023 - nature.com
Head and neck squamous cell carcinoma (HNSCC) undergoes stepwise progression from
normal tissues to precancerous leukoplakia, primary HNSCC, and metastasized tumors. To …
normal tissues to precancerous leukoplakia, primary HNSCC, and metastasized tumors. To …
Oral mucosal organoids as a potential platform for personalized cancer therapy
E Driehuis, S Kolders, S Spelier, K Lõhmussaar… - Cancer discovery, 2019 - AACR
Previous studies have described that tumor organoids can capture the diversity of defined
human carcinoma types. Here, we describe conditions for long-term culture of human …
human carcinoma types. Here, we describe conditions for long-term culture of human …
Tobacco-related carcinogenesis in head and neck cancer
AR Jethwa, SS Khariwala - Cancer and Metastasis Reviews, 2017 - Springer
Head and neck cancer (head and neck squamous cell carcinoma (HNSCC)) is a devastating
disease. Patients require intensive treatment that is often disfiguring and debilitating. Those …
disease. Patients require intensive treatment that is often disfiguring and debilitating. Those …
Translational genomics and recent advances in oral squamous cell carcinoma
Oral squamous cell carcinomas (OSCC) are a heterogeneous group of cancers arising from
the mucosal lining of the oral cavity. A majority of these cancers are associated with lifestyle …
the mucosal lining of the oral cavity. A majority of these cancers are associated with lifestyle …